We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03404856
Previous Study | Return to List | Next Study

Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03404856
Recruitment Status : Unknown
Verified January 2019 by Orpha Labs.
Recruitment status was:  Recruiting
First Posted : January 19, 2018
Last Update Posted : January 25, 2019
Sponsor:
Information provided by (Responsible Party):
Orpha Labs

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Study of ORL-1G in Patients With Glycogen Storage Disease Type 14

Condition or disease Intervention/treatment Phase
Glycogen Storage Disease, Type 14 Drug: ORL-1G - D-galactose Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14
Actual Study Start Date : October 31, 2017
Estimated Primary Completion Date : October 31, 2019
Estimated Study Completion Date : October 31, 2019

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Treatment with ORL-1G - D-galactose Drug: ORL-1G - D-galactose
Oral ORL-1G - D-galactose


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Improvement in liver function. [ Time Frame: 3 months after treatment starts ]
    Statistically significant decrease in plasma liver enzyme levels


Secondary Outcome Measures :
  1. Improvement in serum transferrin glycosylation pattern. [ Time Frame: 30 days after treatment starts ]
    Decreased serum level of hypoglycosylated transferrin.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Glycogen Storage Disease Type 14.
  • Less than 18 years old.

Exclusion Criteria:

  • Diagnosis of any other disease that is not a manifestation of Glycogen Storage Disease Type 14.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03404856


Contacts
Layout table for location contacts
Contact: Study Coordinator Study Coordinator +90 537 763 6241 business.development@orphalabs.com

Locations
Layout table for location information
Turkey
Orpha Labs Recruiting
Ankara, Turkey, 06100
Contact: Study Coordinator Study Coordinator    +905377636241    business.development@orphalabs.com   
Sponsors and Collaborators
Orpha Labs
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Orpha Labs
ClinicalTrials.gov Identifier: NCT03404856    
Other Study ID Numbers: GALA-1
First Posted: January 19, 2018    Key Record Dates
Last Update Posted: January 25, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Orpha Labs:
CDG It; CDGIt PHOSPHOGLUCOMUTASE 1 DEFICIENCY PGM1 DEFICIENCY GLYCOGEN STORAGE DISEASE XIV; GSD14 GSD XIV
Additional relevant MeSH terms:
Layout table for MeSH terms
Glycogen Storage Disease
Metabolic Diseases
Disease
Pathologic Processes
 Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn